SCYNEXIS announced that researchers from Case Western Reserve University in Cleveland have been awarded a competitive research grant of more than $3M by the National Institutes of Health, NIH, to investigate a second generation fungerp developed by SCYNEXIS as a potential treatment for Candida auris (C.auris), a multidrug-resistant yeast that causes serious and often deadly infections. The five-year grant from the National Institute of Allergy and Infectious Diseases of NIH will allow the team led by researchers at the Case Western Reserve School of Medicine and University Hospitals Cleveland Medical Center to evaluate this novel antifungal drug developed by SCYNEXIS. The research team will be led by Mahmoud Ghannoum, Ph.D. "It is thrilling to see the NIH fund this important research to investigate oral and IV SCY-247, one of our patented triterpenoid antifungals, to target drug resistant C. auris, where there is great need due to limited treatment options and the potential to save lives," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "We congratulate Dr. Ghannoum on receiving this grant and want to express our gratitude for his ongoing commitment to patients suffering from terrible and deadly fungal infections."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SCYX:
- SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
- SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
- SCYNEXIS Reports Third Quarter 2022 Financial ResultsĀ and Provides Corporate Update
- Scynexis reports Q3 EPS (62c), consensus (50c)
- Scynexis announces publication of review article on ibrexafungerp